Corona Remedies Limited
Minimum investment
Bidding date
08 Dec - 10 Dec 2025
Price range
₹1,008 - ₹1,062
Minimum quantity
14
Minimum investment
₹14,112
Issue size
₹655.37 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Category | Subscription |
|---|---|
Qualified Institutional Buyers | 114.49x |
Retail Individual Investor | 18.76x |
Non-Institutional Investor | 148.4x |
Others | - |
Total | 18.76x |
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in developing, manufacturing, and marketing prescription-based healthcare products. The company operates across key therapeutic segments including women’s healthcare, cardiology, diabetology, pain management, urology, gastrointestinal care, respiratory, and nutrition. As of June 30, 2025, the company offers 71 brands across multiple therapy categories and has built a strong presence in the Indian Pharmaceutical Market (IPM). Corona Remedies has a large pan-India marketing and distribution network, operated through 2,671 medical representatives across 22 states, enabling deep penetration and strong engagement with hospitals and healthcare professionals. The company operates two manufacturing facilities in Gujarat with a combined installed formulation capacity of 1,285.44 million units per annum, compliant with quality and Good Manufacturing Practice (GMP) standards. With a strong focus on innovation and specialized pharmaceutical products, Corona Remedies continues to expand its footprint in chronic and high-margin therapeutic categories.
Strong Presence in Key Therapeutic Areas: The company operates in chronic and essential care segments like cardio-diabetic and women’s healthcare, which ensures consistent demand.
Pan-India Distribution Network: A strong presence across 22 states with over 2,600 medical representatives supports widespread market penetration.
Modern Manufacturing Capability: The company operates two GMP-certified plants in Gujarat with significant installed capacity for pharmaceutical production.
Financial Growth and Profit Improvement: Revenue and profit trends indicate healthy momentum backed by operational efficiency and expanding market share.
Low Debt with High Return Ratios: Strong metrics including a low debt-to-equity ratio and high ROE/ROCE reflect financial stability and efficient capital usage.
100% Offer for Sale (OFS): The IPO proceeds will not go to the company, which means there is no direct capital infusion for growth plans.
High Valuation at Listing: The pricing may already reflect future growth expectations, which could limit short-term listing gains.
Product Revenue Dependency: Dependence on key brands increases operational risk if demand shifts or competition strengthens in similar categories.
Regulatory and Compliance Exposure: Pharmaceutical pricing controls, policy changes, and compliance norms may affect profitability and operational flexibility.
Competitive Market Environment: The Indian pharmaceutical market is highly competitive, with both domestic and multinational players impacting market share and pricing.
N/A
N/A
N/A
Active IPOs | |
|---|---|
Company name | Bid starts |
Om Power Transmission | 09-04-2026 |
